ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Personalis Inc

Personalis Inc (PSNL)

1.48
0.03
( 2.07% )
Updated: 10:45:23

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.48
Bid
1.47
Ask
1.48
Volume
64,322
1.46 Day's Range 1.49
0.8906 52 Week Range 3.27
Market Cap
Previous Close
1.45
Open
1.48
Last Trade
200
@
1.48
Last Trade Time
10:45:23
Financial Volume
$ 95,295
VWAP
1.4815
Average Volume (3m)
411,048
Shares Outstanding
50,503,889
Dividend Yield
-
PE Ratio
-0.69
Earnings Per Share (EPS)
-2.14
Revenue
73.48M
Net Profit
-108.3M

About Personalis Inc

Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT... Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions. Show more

Sector
Medical Laboratories
Industry
Medical Laboratories
Headquarters
Dover, Delaware, USA
Founded
1970
Personalis Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker PSNL. The last closing price for Personalis was $1.45. Over the last year, Personalis shares have traded in a share price range of $ 0.8906 to $ 3.27.

Personalis currently has 50,503,889 shares outstanding. The market capitalization of Personalis is $74.75 million. Personalis has a price to earnings ratio (PE ratio) of -0.69.

PSNL Latest News

Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company’s NeXT Personal®...

Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring

Blood-based assay uses personalized tumor-informed approach designed to detect cancer recurrence early with an ultra-sensitive approach Personalis, Inc. (Nasdaq: PSNL), a leader in advanced...

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on November 15, 2023 and...

Personalis Reports Fourth Quarter and Full Year 2023 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided...

Form 8-K - Current report

0001527753false00015277532024-02-282024-02-28       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT...

Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Personalis to Participate at Upcoming Investor Conferences

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the following investor conferences: BTIG MedTech, Digital...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.01-0.6711409395971.491.551.391998201.43977254CS
40.1612.12121212121.321.81.314030861.61823567CS
12-0.48-24.48979591841.962.311.124110481.5590977CS
260.2722.31404958681.212.380.89065029601.45849096CS
52-1.1-42.63565891472.583.270.89063711131.66610322CS
156-20.11-93.144974525221.5928.470.89064571758.42444143CS
260-22.22-93.755274261623.753.460.890649576614.77273045CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 25.83
(443.79%)
14.42M
XLOXilio Therapeutics Inc
$ 1.76
(175.43%)
21.48M
BDRXBiodexa Pharmaceuticals PLC
$ 1.62
(88.59%)
58.04M
PEGRProject Energy Reimagined Acquisition Corporation
$ 14.57
(68.24%)
14.81k
PIKKidpik Corporation
$ 4.628
(41.53%)
7.88M
PMECPrimech Holdings Ltd
$ 1.9438
(-49.90%)
1.78M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
GMDAGamida Cell Ltd
$ 0.0434
(-26.69%)
33.61M
UGROUrban Gro Inc
$ 1.37
(-24.52%)
277.08k
KODKodiak Sciences Inc
$ 5.79
(-22.28%)
697.42k
NKLANikola Corporation
$ 1.02
(12.20%)
82.79M
BDRXBiodexa Pharmaceuticals PLC
$ 1.62
(88.59%)
58.04M
AKANAkanda Corporation
$ 0.2003
(21.47%)
51.48M
CISSC3is Inc
$ 0.0341
(-10.73%)
35.53M
GMDAGamida Cell Ltd
$ 0.0434
(-26.69%)
33.61M

PSNL Discussion

View Posts
glenn1919 glenn1919 4 weeks ago
PSNL..................................https://stockcharts.com/h-sc/ui?s=PSNL&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 5 months ago
PSNL new 52=week low
👍️0
ottoman ottoman 6 months ago
Damn, is Cathy dumping? This turd sandwich never taste any better the more I nibble.
👍️0
Monksdream Monksdream 6 months ago
PSNL new 52 week low
👍️0
Invest-in-America Invest-in-America 1 year ago
PSNL: Got some nice REVS/INCOME news late yesterday, Peeps --- could get a little run-up today.
https://pulse2.com/why-the-personalis-stock-increased-over-10-psnl/
👍️0
Timetravelerdos Timetravelerdos 3 years ago
Personalis Announces Delivery of the 100,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, announced today that it has delivered the 100,000th whole human genome sequence dataset to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). Although Personalis has been contracted by the VA MVP since 2012, the program has accelerated and over 50,000 of these genomes have been delivered in 2020.

"The VA MVP is the largest whole genome sequencing project in the United States and this is a significant milestone for both the program and for Personalis," said John West, Chief Executive Officer. "Population-scale sequencing projects of this nature represent a cornerstone in our effort to accelerate the advancement of precision medicine across a wide range of disease areas. With our sizable investments in the technology and infrastructure, necessary to win and execute these projects, Personalis sees population genomics and health as key priorities for our company. We congratulate the VA MVP for their visionary leadership and note that VA scientists now list over 50 peer reviewed publications from the Program."

https://finance.yahoo.com/news/personalis-announces-delivery-100-000th-210700535.html
👍️0
JGrumby JGrumby 5 years ago
Hearing that Monday PSNL will start to get Wall street research reports. Look at PSNL vs GH and NVTA etc
👍️0
JGrumby JGrumby 5 years ago
Nice day after the post IPO sell off.
👍️0

Your Recent History

Delayed Upgrade Clock